Related Experiment Video
Updated: Jun 23, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Proton-Pump Inhibitors to Prevent Gastrointestinal Bleeding - An Updated Meta-Analysis.
Ying Wang1, Sameer Parpia2, Long Ge3
1Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Proton-pump inhibitors effectively prevent upper gastrointestinal bleeding in critically ill patients. However, their impact on mortality is uncertain and may vary by disease severity, warranting careful consideration.
Area of Science:
- Critical Care Medicine
- Gastroenterology
- Pharmacology
Background:
- Stress ulcer prophylaxis is crucial for critically ill patients.
- Proton-pump inhibitors (PPIs) are commonly used for this purpose.
- Evidence on PPI efficacy and safety in this population requires synthesis.
Purpose of the Study:
- To systematically review the efficacy and safety of PPIs for stress ulcer prophylaxis.
- To evaluate PPIs' impact on bleeding, mortality, and infections in critically ill adults.
- To explore potential differential effects of PPIs on mortality based on disease severity.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Included 12 trials with 9533 critically ill adult patients.
- Assessed certainty of evidence using GRADE and credibility of subgroup analyses.
Main Results:
- PPIs significantly reduced clinically important upper gastrointestinal bleeding (high certainty).
- PPIs showed little to no effect on overall mortality (low certainty).
- Subgroup analysis suggested PPIs may decrease mortality in less severely ill patients but increase it in more severely ill patients.
Conclusions:
- High certainty evidence supports PPIs for reducing upper gastrointestinal bleeding.
- PPIs' effect on mortality is uncertain and may be severity-dependent.
- Further research may clarify PPIs' role in specific patient subgroups.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

